Labophar SA
Labophar reported revenue of 406,703 € for the 2025 financial year (annual accounts filed with the NBB on 30 Jun 2026).
The score of Labophar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue -91 % Equity -34 % Total assets -23 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Labophar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 406,703 € | ||||
| Net result | −375,714 € | ||||
| Equity | €2.48m | ||||
| EBITDA | 419,808 € | ||||
| Total assets | €8.65m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jun 2026
- Year ended 31 Dec 2024filed on 22 Jul 2025
- Year ended 31 Dec 2023filed on 08 Jul 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 11 Jul 2022
Labophar's financial analysis
- Solvency28.6%sector median: 29.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Labophar
Labophar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0643.723.177
- VAT number
- BE0643723177
- Peppol
- Registered · 0208:0643723177 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 30 Nov 2015
- Registered office
- 9051 Ghent
- Latest accounts
- 2025 · filed on 30 Jun 2026
- Activity
- Buying and selling of own real estate (NACE 68110)
Labophar (SA) has been based in Ghent since 2015, active in: buying and selling of own real estate. For 2025, it reports revenue of 406,703 €, a net loss of 375,714 € and equity of €2.48m. Its solvency stands at 28.6%, below the median of its sector (29.5%).
Companies similar to Labophar
Companies in the same business, of comparable size and area, outside its group.
- SPGL Ltd Wholesale of pharmaceutical and medical goods · balance sheet €1.01m
- M.Ex.T. BELGIUM Wholesale of pharmaceutical and medical goods Roeselare · balance sheet €13.6m
- Almirall Wholesale of pharmaceutical and medical goods Zaventem · balance sheet €7.75m
- Romed Wholesale of pharmaceutical and medical goods Hoogstraten · balance sheet €9.52m
- Hefra Wholesale of pharmaceutical and medical goods Turnhout · balance sheet €10.7m
- Valerco Wholesale of pharmaceutical and medical goods Kontich · balance sheet €12.9m
- RMS Medical Devices Wholesale of pharmaceutical and medical goods Roosdaal · balance sheet €10.4m
- Lundbeck Wholesale of pharmaceutical and medical goods Ixelles · balance sheet €13.7m
Frequently asked questions about Labophar
What is the revenue of Labophar?
According to the 2025 annual accounts filed with the NBB, the revenue of Labophar amounts to 406,703 €.
What is the VAT number of Labophar?
In Belgium, the VAT number is the company number prefixed with BE: BE0643723177 for Labophar, if the company is VAT-registered. Its company number (CBE) is 0643.723.177.
Where is the registered office of Labophar?
According to the CBE register, the registered office of Labophar is in 9051 Ghent.
What is the equity of Labophar?
At the close of the 2025 financial year, the equity of Labophar amounts to 2,477,822 €, a solvency of 28.6% of total assets.
Who manages Labophar?
The register lists 7 active mandates at Labophar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Labophar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →